Correction to “LncRNA-HCP5 Regulates KLF5 by ceRNA and m6A Pathways to Inhibit the Progression of Osteoarthritis”

IF 2.4 4区医学 Q2 RHEUMATOLOGY

International Journal of Rheumatic Diseases Pub Date : 2025-04-23 DOI:10.1111/1756-185X.70223

{"title":"Correction to “LncRNA-HCP5 Regulates KLF5 by ceRNA and m6A Pathways to Inhibit the Progression of Osteoarthritis”","authors":"","doi":"10.1111/1756-185X.70223","DOIUrl":null,"url":null,"abstract":"P. Jiang, Y. Song, P. Li, Y. Yang and J. Zhang, “LncRNA-HCP5 Regulates KLF5 by ceRNA and m6A Pathways to Inhibit the Progression of Osteoarthritis,” International Journal of Rheumatology 28, no. 1 (2025): e70035, https://doi.org/10.1111/1756-185X.70035.There are errors in the article title. The correct article title is “LncRNA-HCP5 Regulates KLF5 by ceRNA and m6A Pathways to Inhibit the Progression of Osteoarthritis”.There are errors in the affiliations. The correct affiliations should be “1 Department of Orthopedics, Shaanxi Rehabilitation Hospital, Xi'an, Shaanxi, China; 2 Department of Occupational Therapy, Shaanxi Rehabilitation Hospital, Xi'an, Shaanxi, China”.The description of Figure 4D is missing from the end of Section 3.4. The description should be “Further research revealed that ov-HCP5 significantly increased the expression of the methyltransferase METTL3, while DZNeP inhibited the expression of METTL3 (Figure 4D).”The online article has been corrected.We apologize for the errors.","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 4","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70223","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Rheumatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1756-185X.70223","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

P. Jiang, Y. Song, P. Li, Y. Yang and J. Zhang, “LncRNA-HCP5 Regulates KLF5 by ceRNA and m6A Pathways to Inhibit the Progression of Osteoarthritis,” International Journal of Rheumatology 28, no. 1 (2025): e70035, https://doi.org/10.1111/1756-185X.70035.

There are errors in the article title. The correct article title is “LncRNA-HCP5 Regulates KLF5 by ceRNA and m6A Pathways to Inhibit the Progression of Osteoarthritis”.

There are errors in the affiliations. The correct affiliations should be “1 Department of Orthopedics, Shaanxi Rehabilitation Hospital, Xi'an, Shaanxi, China; 2 Department of Occupational Therapy, Shaanxi Rehabilitation Hospital, Xi'an, Shaanxi, China”.

The description of Figure 4D is missing from the end of Section 3.4. The description should be “Further research revealed that ov-HCP5 significantly increased the expression of the methyltransferase METTL3, while DZNeP inhibited the expression of METTL3 (Figure 4D).”

The online article has been corrected.

We apologize for the errors.

查看原文本刊更多论文

修正“LncRNA-HCP5通过ceRNA和m6A途径调控KLF5抑制骨关节炎进展”

姜萍，宋艳，李鹏，杨艳，张军，“LncRNA-HCP5通过ceRNA和m6A途径调控KLF5抑制骨关节炎的进展，国际风湿病杂志，28,no. 5。1 (2025): e70035, https://doi.org/10.1111/1756-185X.70035.There均为文章标题错误。正确的文章标题是“LncRNA-HCP5通过ceRNA和m6A途径调控KLF5抑制骨关节炎的进展”。在从属关系中存在错误。正确的隶属单位应为“1陕西省康复医院骨科，中国陕西省西安市；2陕西省康复医院职业治疗科，陕西西安；3.4节末尾缺少对图4D的描述。描述应该是“进一步研究发现ov-HCP5显著增加了甲基转移酶METTL3的表达，而DZNeP抑制了METTL3的表达（图4D）。”网上的文章已被更正。我们为错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Rheumatic Diseases RHEUMATOLOGY-

CiteScore

3.70

自引率

4.00%

发文量

362

审稿时长

1 months

期刊介绍： The International Journal of Rheumatic Diseases (formerly APLAR Journal of Rheumatology) is the official journal of the Asia Pacific League of Associations for Rheumatology. The Journal accepts original articles on clinical or experimental research pertinent to the rheumatic diseases, work on connective tissue diseases and other immune and allergic disorders. The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor.